Physician profile
Mitchell J Binder
NPI 1043282155
$3,180.79
in general payments reported to CMS, 2019-2025
37 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $11.77 · 2023: $232 · 2024: $792 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $527.75 | 2019-2025 | |
| Janssen Biotech, INC. | $214.57 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Pfizer INC. | $163.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $156.11 | 2019-2025 | Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $149.42 | 2019-2024 | Alunbrig, Fruzaqla |
| Seagen INC. | $142.46 | 2019-2023 | Adcetris |
| Gilead Sciences, INC. | $138.02 | 2023-2025 | Trodelvy |
| Genentech USA, INC. | $132.78 | 2019-2024 | Perjeta, Phesgo, Venclexta |
| Glaxosmithkline, LLC. | $128.30 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Eisai INC. | $127.53 | 2019-2025 | |
| Daiichi Sankyo INC. | $108.69 | 2024-2025 | Enhertu |
| Astrazeneca Pharmaceuticals Lp | $96.96 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Foundation Medicine, INC. | $94.33 | 2019 | |
| Astellas Pharma US INC | $90.68 | 2019-2025 | Xtandi, Xospata |
| Sobi, INC | $75.99 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $74.32 | 2019-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $68.56 | 2019-2023 | Keytruda, Lynparza |
| Kite Pharma, INC. | $66.01 | 2024-2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $64.19 | 2019-2024 | Ultomiris |
| Puma Biotechnology, INC. | $53.63 | 2025 | |
| Amgen INC. | $53.30 | 2019 | |
| Celgene Corporation | $48.09 | 2019-2025 | Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.44 | 2019 | |
| Incyte Corporation | $44.94 | 2024-2025 | Jakafi |
| Genmab U.S., INC. | $39.40 | 2024-2025 | Epkinly |
| Springworks Therapeutics, INC. | $36.34 | 2024-2025 | Ogsiveo |
| Bayer Healthcare Pharmaceuticals INC. | $33.90 | 2019-2025 | |
| Beone Medicines USA, INC. | $31.89 | 2025 | Brukinsa |
| Array Biopharma INC | $31.47 | 2019-2024 | Mektovi, Braftovi, Tukysa |
| Rigel Pharmaceuticals, INC. | $24.66 | 2019-2024 | Rezlidhia, Tavalisse |
| Lilly USA, LLC | $23.36 | 2019 | |
| Deciphera Pharmaceuticals INC. | $17.96 | 2025 | Romvimza, Qinlock |
| Tempus Ai, INC | $17.79 | 2024 | |
| Genzyme Corporation | $16.70 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.61 | 2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $15.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Binder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.